<DOC>
	<DOCNO>NCT01017731</DOCNO>
	<brief_summary>The purpose study determine Ramucirumab ( IMC-1121B ) cause prolongation QT/QTc interval participant advance cancer .</brief_summary>
	<brief_title>Study Ramucirumab ( IMC-1121B ) Therapy Corrected QT ( QTc ) Interval Changes</brief_title>
	<detailed_description>The primary purpose study determine treatment ramucirumab cause prolongation QTc/QT interval participant advance cancer , assess safety tolerability ramucirumab therapy , evaluate pharmacokinetic ( PK ) characteristic ramucirumab</detailed_description>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>The participant histologically document advanced metastatic malignant cancer solid tumor origin respond standard therapy standard therapy available The participant resolution adverse event prior anticancer therapy Performance status 0 2 The participant ≥ 18 year age The participant able provide inform write consent amenable compliance protocol schedule test The participant adequate liver , kidney , blood , blood clot function define trial entrance criteria The participant agree use adequate contraception study period 8 week last dose study treatment The participant anticancer therapy within 14 day ( 6 week nitrosoureas mitomycin C ) prior enter study The participant therapeutic radiotherapy within 14 day prior enter study The participant ongoing side effect ≥ Grade 2 due prior anticancer therapy The participant brain leptomeningeal metastases The participant history uncontrolled severe cardiac disease The participant history severe congestive heart failure ( CHF ) The participant known history arterial thrombotic event The participant know history significant peripheral arterial disease ( PAD ) The participant implantable pacemaker automatic implantable cardioverter defibrillator ( AICD ) The participant history risk factor ventricular tachycardia Torsades de pointes ( TdP ) [ example , family history ( parent sibling ) long QT syndrome ] , history fainting , unexplained loss consciousness , convulsions The participant systolic blood pressure ( SBP ) &gt; 150 millimeter mercury ( mmHg ) &lt; 90 mmHg diastolic blood pressure ( DBP ) &lt; 45 &gt; 95 mmHg . ( Participants history hypertension receive antihypertensive therapy permit study provide blood pressure within parameter detail ) The participant heart rate &lt; 50 beat per minute ( bpm ) &gt; 100 bpm rest The participant clinically relevant abnormality ECG , prevent accurate measurement QT interval The participant use medication know prolong ECG QT interval The participant know allergy treatment component include fluoroquinolone antibiotics The participant receive investigational new drug device within 14 day prior enrollment study ( exclude placement intravenous access device ) The participant undergone major surgery within 28 day prior enrollment The participant know human immunodeficiency virus ( HIV ) infection The participant , female , pregnant lactate The participant receive chronic daily treatment aspirin [ &gt; 325 milligram per day ( mg/day ) ] The participant concurrent active malignancy adequately treat nonmelanomatous skin cancer , noninvasive carcinoma , situ neoplasm The participant psychological , familial , sociological , geographical condition permit adequate study followup , compliance protocol , signature Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Advanced Solid tumor</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>QTc</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Malignant</keyword>
</DOC>